{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:23:20Z","timestamp":1762928600581},"reference-count":51,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.gastrohep.2018.06.010","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T01:07:25Z","timestamp":1532480845000},"page":"576-582","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Agentes anti-factor de necrosis tumoral en enfermedad de Crohn y colitis ulcerosa: m\u00e1s all\u00e1 de la enfermedad luminal"],"prefix":"10.1016","volume":"41","author":[{"given":"Laura","family":"N\u00fa\u00f1ez-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Mesonero-Gismero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agust\u00edn","family":"Albillos-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"L\u00f3pez-Sanrom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2018.06.010_bib0260","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clin Immunol"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0265","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0270","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.gastrohep.2016.01.011","article-title":"Inflammatory bowel disease as a paradoxical effect of anti-TNF alpha therapy","volume":"40","author":"Iriarte","year":"2017","journal-title":"Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0275","unstructured":"U.S. Food & Drug Administration. 2018. Disponible en: https:\/\/www.fda.gov\/Drugs\/default.htm"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0280","unstructured":"European Medicines Agency. 2018. Disponible en: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0285","doi-asserted-by":"crossref","first-page":"203","DOI":"10.15403\/jgld.2014.1121.242.bezz","article-title":"Overview of biological therapy in ulcerative colitis: Current and future directions","volume":"24","author":"Furfaro","year":"2015","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0290","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00384-012-1602-8","article-title":"Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: A systematic review and meta-analysis","volume":"28","author":"Chang","year":"2013","journal-title":"Int J Colorectal Dis."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0295","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0300","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn's disease","volume":"350","author":"Sands","year":"2004","journal-title":"N Engl J Med."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0305","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1177\/1756283X08092548","article-title":"Efficacy and safety of adalimumab in Crohn's disease","volume":"1","author":"Lichtenstein","year":"2008","journal-title":"Therap Adv Gastroenterol."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0310","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2010.06.070","article-title":"Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort","volume":"139","author":"Thia","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0315","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/gutjnl-2012-304353","article-title":"Crohn's disease complicated by strictures: A systematic review","volume":"62","author":"Rieder","year":"2013","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0320","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1053\/j.gastro.2008.07.069","article-title":"Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: Results from the CHARM study","volume":"135","author":"Feagan","year":"2008","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0325","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/bjs.1800750711","article-title":"Natural history and treatment of anorectal strictures complicating Crohn's disease","volume":"75","author":"Linares","year":"1988","journal-title":"Br J Surg"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0330","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s10350-004-0536-9","article-title":"Results of surgical removal of the pouch after failed restorative proctocolectomy","volume":"47","author":"Karoui","year":"2004","journal-title":"Dis Colon Rectum."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0335","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5217\/ir.2015.13.1.19","article-title":"Intestinal stricture in Crohn's disease","volume":"13","author":"Chang","year":"2015","journal-title":"Intest Res."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0340","doi-asserted-by":"crossref","DOI":"10.1111\/jgh.14119","article-title":"Crohn's disease associated strictures","author":"Chan","year":"2018","journal-title":"J Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0345","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/ajg.2014.424","article-title":"Characterization of inflammation and fibrosis in Crohn's disease lesions by magnetic resonance imaging","volume":"110","author":"Rimola","year":"2015","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0350","first-page":"2503","article-title":"Intestinal strictures complicating initially successful infliximab treatment for luminal Crohn's disease","volume":"95","author":"Vasilopoulos","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0355","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/j.1572-0241.2006.00463.x","article-title":"Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease","volume":"101","author":"Lichtenstein","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0360","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3748\/wjg.14.1885","article-title":"Effect of infliximab on small bowel stenosis in patients with Crohn's disease","volume":"14","author":"Pallotta","year":"2008","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0365","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/gutjnl-2016-312581","article-title":"Laharie D. Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study","volume":"67","author":"Bouhnik","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0370","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/gut.14.11.865","article-title":"Abscess and fistulae in Crohn's disease","volume":"14","author":"Steinberg","year":"1973","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0375","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1572-0241.2004.04083.x","article-title":"Type of fistula determines response to infliximab in patients with fistulous Crohn's disease","volume":"99","author":"Parsi","year":"2004","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0380","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohn's disease","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0385","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ajg.2014.183","article-title":"Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: A cohort study from the GETAID","volume":"109","author":"Amiot","year":"2014","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4321\/S1130-01082013000100002","article-title":"Enterocutaneous fistulas and Croh\u0144s disease: Clinical characteristics and response to treatment","volume":"105","author":"G\u00f3mez-Senent","year":"2013","journal-title":"Rev Esp Enferm Dig."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0395","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/ecco-jcc\/jjw016","article-title":"Outcomes of medical and surgical therapy for entero-urinary fistulas in Crohn's disease","volume":"10","author":"Taxonera","year":"2016","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0400","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.crohns.2011.08.015","article-title":"Genital fistulas in female Crohn's disease patients: Clinical characteristics and response to therapy","volume":"6","author":"De la Poza","year":"2012","journal-title":"J Crohns Colitis."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0405","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9270(02)05909-9","article-title":"Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease","volume":"98","author":"Van Assche","year":"2003","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0410","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1365-2036.2006.02878.x","article-title":"Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: Results from the ACCENT II study","volume":"23","author":"Sands","year":"2006","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0415","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ibd.21783","article-title":"Abdominal phlegmons in Crohn's disease: Outcomes following antitumor necrosis factor therapy","volume":"18","author":"Cullen","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0420","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.gastro.2003.08.025","article-title":"American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn's disease","volume":"125","author":"Sandborn","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0425","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1365-2036.2009.04089.x","article-title":"Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab","volume":"30","author":"Bouguen","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0430","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0435","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1111\/j.1572-0241.2005.00278.x","article-title":"Clinical approach to diseases of ileal pouchanal anastomosis","volume":"100","author":"Shen","year":"2005","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0440","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/ibd\/izx049","article-title":"Systematic review with meta-analysis: Anti-TNF therapy in refractory pouchitis and Crohn's disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis","volume":"24","author":"Huguet","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0445","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/MIB.0000000000001109","article-title":"Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the Swiss IBD cohort study","volume":"23","author":"Vavricka","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ibd.21663","article-title":"Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE","volume":"18","author":"L\u00f6fberg","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0455","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cgh.2016.06.025","article-title":"Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease","volume":"15","author":"Peyrin-Biroulet","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0460","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut."},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0465","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4321\/S1130-01082012000900004","article-title":"Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn's disease","volume":"104","author":"Barreiro-de-Acosta","year":"2012","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0470","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0475","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1007\/s10620-013-2762-2","article-title":"Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease","volume":"58","author":"Arg\u00fcelles-Arias","year":"2013","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0480","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2174\/1389450115666140908125453","article-title":"Biologics for extraintestinal manifestations of IBD","volume":"15","author":"Vavricka","year":"2014","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0485","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1365-2036.2004.02152.x","article-title":"Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease","volume":"20","author":"Franchimont","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0490","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1097\/MIB.0000000000000417","article-title":"The influence of anti-tumor necrosis factor agents on hemoglobin levels of patients with inflammatory bowel disease","volume":"21","author":"Koutroubakis","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0495","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","article-title":"Third European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical management and special situations","author":"Gionchetti","year":"2017","journal-title":"J Crohn Colitis"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0500","article-title":"F\u00edstula enterourinaria como debut de enfermedad de Crohn: manejo terap\u00e9utico a prop\u00f3sito de un caso. Experiencias terap\u00e9uticas en enfermedad inflamatoria intestinal","author":"Mesonero","year":"2017","journal-title":"Pr\u00e1ct Cl\u00edn"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0505","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","author":"Harbord","year":"2016","journal-title":"J Crohn Colitis"},{"key":"10.1016\/j.gastrohep.2018.06.010_bib0510","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.crohns.2014.08.012","article-title":"European evidence based consensus on surgery for ulcerative colitis","volume":"9","author":"\u00d8resland","year":"2015","journal-title":"J Crohn Colitis"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057051830195X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021057051830195X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T16:39:39Z","timestamp":1604680779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021057051830195X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S021057051830195X"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2018.06.010","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Agentes anti-factor de necrosis tumoral en enfermedad de Crohn y colitis ulcerosa: m\u00e1s all\u00e1 de la enfermedad luminal","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2018.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}